AloCelyvir
Sponsors
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL, Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, José María Piulats Rodríguez
Conditions
Autoimmune refractory epilepsy and Rasmussen EncephalitisDiffuse Intrinsic Pontine GliomaHigh-risk relapsed/refractory (R/R) neuroblastoma (NB).Medulloblastoma, Childhood, RecurrentNewly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in childrenRelapsed or refractory extracranial solid tumors in children and adolescents.Uveal Melanoma, Metastaticadolescents and young adults.
Phase 1
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
Active, not recruitingNCT04758533
Start: 2021-04-19End: 2026-04-30Updated: 2024-12-27
Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma
NCT05047276
Start: 2021-10-01End: 2024-12-31Target: 16Updated: 2021-09-17
Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagnosed diffuse intrinsic pointine glioma (DIPG) in combination with radiotherapy or medulloblastoma in relapse/progression in monotherapy.
Active, not recruitingCTIS2022-502516-37-00
Start: 2021-07-12Target: 12Updated: 2023-03-15
Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM)
CompletedCTIS2024-515032-76-00
Start: 2021-11-10End: 2025-09-09Target: 16Updated: 2024-09-06
Feasibility clinical trial of the combination of AloCelyvir with chemotherapy and radiotherapy for the treatment of children and adolescents with relapsed or refractory extracranial solid tumors.
Not yet recruitingCTIS2024-518417-25-00
Target: 24Updated: 2024-10-10
Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesenchymal cells in children and adolescents with refractory epilepsies.
Not yet recruitingCTIS2024-520427-86-00
Target: 10Updated: 2025-01-24
Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma
WithdrawnCTIS2025-522006-21-00
Target: 15Updated: 2026-08-03